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Studies proved that among all a1 -adrenoceptors, cardiac myocytes functionally express 
only a1A- and a1B-subtype. Scientists indicated that a1A-subtype blockade might be 
beneficial in restoring normal heart rhythm. Therefore, we aimed to determine the role of 
a1-adrenoceptors subtypes (i.e., a1A and a1B) in antiarrhythmic effect of six structurally 
similar derivatives of 2-methoxyphenylpiperazine. We compared the activity of studied 
compounds with carvedilol, which is ß1 - and a1 -adrenoceptors blocker with antioxidant 
properties. To evaluate the affinity for adrenergic receptors, we used radioligand 
methods. We investigated selectivity at a1-adrenoceptors subtypes using functional 
bioassays. We tested antiarrhythmic activity in adrenaline-induced (20 ^g/kg i.v.), calcium 
chloride-induced (140 and 25 mg/kg i.v.) and barium chloride-induced (32 and 10 mg/kg 
i.v.) arrhythmia models in rats. We also evaluated the influence of studied compounds 
on blood pressure in rats, as well as lipid peroxidation. All studied compounds 
showed high affinity toward a1-adrenoceptors but no affinity for ß1 receptors. 
Biofunctional studies revealed that the tested compounds blocked a1A-stronger than 
a1B-adrenoceptors, but except for HBK-19 they antagonized a1A-adrenoceptor weaker 
than a1D-subtype. HBK-19 showed the greatest difference in pA2 values—it blocked 
a1A-adrenoceptors around seven-fold stronger than a1B subtype. All compounds 
showed prophylactic antiarrhythmic properties in adrenaline-induced arrhythmia, but 
only the activity of HBK-16, HBK-17, HBK-18, and HBK-19 (ED50 =  0.18-0.21) 
was comparable to that of carvedilol (ED50 =  0.36). All compounds reduced 
mortality in adrenaline-induced arrhythmia. HBK-16, HBK-17, HBK-18, and HBK-19 
showed therapeutic antiarrhythmic properties in adrenaline-induced arrhythmia. None
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of the compounds showed activity in calcium chloride- or barium chloride-induced 
arrhythmias. HBK-16, HBK-17, HBK-18, and HBK-19 decreased heart rhythm at ED84. 
All compounds significantly lowered blood pressure in normotensive rats. HBK-18 
showed the strongest hypotensive properties (the lowest active dose: 0.01 mg/kg). 
HBK-19 was the only compound in the group, which did not show hypotensive effect 
at antiarrhythmic doses. HBK-16, HBK-17, HBK-18, HBK-19 showed weak antioxidant 
properties. Our results indicate that the studied 2-methoxyphenylpiperazine derivatives 
that possessed stronger a1A-adrenolytic properties (i.e., HBK-16, HBK-17, HBK-18, 
and HBK-19) were the most active compounds in adrenaline-induced arrhythmia. Thus, 
we suggest that the potent blockade of a1A-receptor subtype is essential to attenuate 
adrenaline-induced arrhythmia.
Keywords: arrhythmia, antiarrhythmic agents, # 1 -adrenolytics, 2-methoxyphenylpiperazine, a^Ą-adrenoceptor 
antagonist, a^g-adrenoceptor antagonist, a^p-adrenoceptor antagonist, hypotensive
INTRODUCTION
Arrhythmias are the most common causes of sudden cardiac 
death (Deo and Albert, 2012). Despite numerous antiarrhythmic 
drugs, pharmacotherapy is still ineffective in majority of patients. 
Moreover, all antiarrhythmic agents acting via different ion 
channels possess life-threatening proarrhythmic potential. Thus, 
scientists are still looking for effective and safe compounds, 
which will protect against arrhythmia and/or restore normal 
heart rhythm.
Antiarrhytmic activity of pharmacological agents resulting 
from their receptor-based mechanisms might be equally efficient 
and much safer than that observed for classical antiarrhythmic 
drugs. According to many studies, a 1-adrenolytics may have 
potential in the treatment of arrhythmias. Scientists agree that 
the blockade of a 1-, and particularly a 1A-adrenoceptor may be 
beneficial in restoring normal heart rhythm (reviewed in Hieble, 
2000 and Shannon and Chaudhry, 2006). The a 1-adrenoceptor 
stimulation results in inositol trisphosphate (IP3) production, 
and subsequent Ca2+ release from the sarcoplasmatic reticulum 
(SR; Escobar et al., 2012). Although the regulation of Ca2+ level 
in cardiomyocytes mainly depends on ryanodine receptors and 
SR Ca2+ pump, the increased basal level of Ca2+ induced by 
IP3  may also alter the electrical excitability of cardiomyocytes, 
thus contributing to the development of arrhythmia e.g., atrial 
(Zima and Blatter, 2004) or ventricular fibrillation (Proven et al., 
2006). Thereby, the blockade of (^-adrenoceptors may lead to 
the stabilization of Ca2+ level producing antiarrhythmic effect in 
arrhythmias induced by catecholamines e.g., catecholaminergic 
polymorphic ventricular tachycardia. The above hypothesis was 
supported by Suita et al. (2015), who demonstrated that prazosin 
not only shortened norepinephrine-induced elongation of atrial 
fibrillation in mice, but also attenuated norepinephrine-induced 
SR Ca2+ leak and spontaneous SR Ca2+ release in cultured 
atrium cardiomyocytes. This proves that a 1 -adrenoceptors may 
have role in preventing cardiac arrhythmias. Numerous animal 
studies confirmed this theory, showing antiarrhythmic properties 
of a 1 -adrenolytics (Sapa et al., 2011; Kubacka et al., 2013a; Rapacz 
etal., 2014, 2015b).
Since in our earlier experiments 2-methoxyphenylpiperazine 
derivatives showed high affinity toward a 1-adrenoceptors 
(Pytka et al., 2015), in this study we aimed to determine 
the role of a 1-adrenoceptors subtypes (i.e., a 1A, a 1B) in 
antiarrhythmic effect of six structurally similar derivatives of 2- 
methoxyphenylpiperazine. We compared the activity of studied 
compounds with carvedilol, which is ß1- and a 1-adrenoceptors 
blocker with antioxidant properties.
MATERIALS AND METHODS 
Animals
The experiments were carried out using male normotensive 
Wistar rats [Krf: (WI) WU], weighing 200-250 g. Animals were 
kept in plastic cages (three rats per cage) at constant room 
temperature of 22 ±  20C, with 12:12 h  light/dark cycle. Rats 
had free access to food (standard pellet diet) and water. Each 
experimental and control groups consisted of four to six animals. 
The animals were killed by cervical dislocation immediately 
after the experiment. All injections were given in a volume of1 
ml/kg. All experimental procedures were approved by the Local 
Ethics Committee for Experiments on Animals of the Jagiellonian 
University in Krakow, Poland (approval numbers 110/2014 and 
246/2015) and cared for in accordance with the Guide to the Care 
and Use of Experimental Animals.
Drugs
Six studied compounds (Figure 1): 1-[(2,6-dimethylphenoxy) 
ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride 
(HBK14), 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2- 
methoxyphenyl)piperazine hydrochloride (HBK15), 1N  -[3- 
(2-chloro-5-methylphenoxy)propyl]-4N-(2-methoxyphenyl) 
piperazine hydrochloride (HBK16), 1N-[3-(2,5-dimethylpheno 
xy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride 
(HBK17), and 1N-[3-(2,4,6-trimethylphenoxy)propyl]-4N-(2- 
methoxyphenyl)piperazine hydrochloride (HBK18), 1N-[3-(2,3, 
5-trimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine 
hydrochloride (HBK-19) were synthesized in the Department
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FIGURE 1 | The chemical structures of tested 2-methoxyphenylpiperazine derivatives. HBK-14, 1-[(2,6-dimethylphenoxy)ethoxyethyl]-4-(2-methoxyp 
henyl)piperazine hydrochloride; HBK-15, 1-[(2-chloro-6-methylphenoxy)ethoxyethyl]-4-(2-methoxyphenyl)piperazine hydrochloride; HBK-16, 1N-[3-(2-chloro-5-meth 
ylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride; HBK-17, 1N-[3-(2,5-dimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride; 
HBK-18, 1N-[3-(2,4,6-trimethylphenoxy)propyl]-4N-(2-methoxyphenyl)piperazine hydrochloride; HBK-19, 1N-[3-(2,3,5-trimethylphenoxy)propyl]-4N-(2-methoxyphe 
nyl)piperazine hydrochloride.
of Bioorganic Chemistry, Chair of Organic Chemistry, Faculty 
of Pharmacy, Jagiellonian University (Waszkielewicz et al., 
2015). The investigated compounds were dissolved in saline 
and administered intraperitoneally (i.p.) or intravenously (i.v.). 
Thiopental (Rotexmedica, Germany) was dissolved in saline 
and administered i.p. Chloroethylclonidine (Sigma, Germany), 
noradrenaline (Sigma, Germany), johimbine (Tocris, United 
Kingdom), propranolol (Fluka, USA), phentolamine (Sigma, 
Germany) were dissolved in saline or dimethyl sulfoxide (DMSO, 
Sigma, Germany) and used in radioligand or biofunctional 
studies. Adrenaline (Polfa S.A., Warsaw), carvedilol (Sigma, 
Germany), methoxamine (Sigma, China), calcium chloride 
(Fluka, Germany), and barium chloride (Sigma, Germany) were 
dissolved in saline and administered i.v. Heparin (Polfa S.A., 
Warsaw) was used as anticoagulant during experiments. The 
control groups received 0.9% NaCl solution. Other chemicals 
used were obtained from POCh (Polish Chemical Reagents, 
Poland).
Radioligand Binding Assay
The a 1- and ß^adrenoceptor radioligand binding assay was 
performed on rat cerebral cortex. [3H]-prazosin (19.5 Ci/mmol, 
a 1-adrenoceptor) and [3H]-CGP-12177 (48 Ci/mmol, ß1-
adrenergic receptor) were used. The brains were homogenized 
in 20 volumes of an ice-cold 50 mM Tris-HCl buffer (pH
7.6) and were centrifuged at 20,000 x  g for 20 min ( 0 - 40C). 
The cell pellet was resuspended in the Tris-HCl buffer and 
centrifuged again. Radioligand binding assays were performed 
in plates (MultiScreen/Millipore). The final incubation mixture 
(final volume 300 |xl) consisted of 240 |xl of the membrane 
suspension, 30 |xl of [3H]-prazosin (0.2 nM), [3H]-CGP- 
12177 (0.2 nM) solution and 30 |xl of the buffer containing 
seven to eight concentrations (10-11 — 10- 4 M) of the tested 
compounds. In order to measure the unspecific binding, 
10 |xM phentolamine (for [3H]-prazosin) and 1 |xM of 
propranolol (for [3H]-CGP-12177) were applied. The incubation 
was terminated by rapid filtration through glass fiber filters 
(W hatman GF/C) using a vacuum manifold (Millipore). 
The filters were then washed twice with the assay buffer and 
placed in scintillation vials with a liquid scintillation cocktail. 
Radioactivity was measured in a WALLAC 1409 DSA liquid 
scintillation counter (Perkin Elmer, USA). All the assays were 
made in duplicate and the inhibitory constants (Ki) were 
estimated.
Influence on a1A-Adrenoceptors: Rat Tail 
Artery
Rats were anesthetized with thiopental (75 mg/kg i.p.) and the 
middle part of the ventral caudal artery was removed, cleaned 
of surrounded tissues and uncovered of endothelium by gentle
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rubbing in the Krebs-Henseleit solution. The isolated artery, 
cut into ^ 4  mm  long rings, was then horizontally put up 
between two stainless steel hooks (diameter 0.15 mm). One 
hook was fastened to the bottom  of the chamber and the other 
to an isometric FDT10-A force displacement transducer (DMT 
Model 750TOBS, Denmark), linked with Powerlab 4/26 analyzer 
(ADInstruments), and processed by LabChart 7 software. The 
isolated rings were incubated in the Krebs-Henseleit solution 
(20 ml) at the temperature 370C and pH 7.4 with constant 
oxygenation (O2/CO2, 19:1). The initial optimal tissues tension 
was set at 0.75 g. Chloroethylclonidine (3 ^M ) as the preferential 
a 1B-adrenoreceptor alkylating agent was used during incubation 
and after 30 min it was completely washed off. Through 100 min 
of equilibration tissues were stimulated with noradrenaline 
(1 ^M ) four times with washing out until the contractile 
response become constant. Two cumulative concentration- 
response curves to noradrenaline, at an interval of 60 min, 
were established on each arterial ring both in the presence and 
absence of antagonist. The incubation with antagonists went on 
for 30 min. The experiments were carried out in the constant 
presence of yohimbine (0.1 ^M ) and propranolol (1 ^M ) to 
block a 2- and ß-adrenoceptors, respectively in order to minimize 
the involvement of these adrenoceptors in the response to 
noradrenaline.
Influence on a1B-Adrenoceptors: Mouse 
Spleen
The influence on a 1B-adrenoceptors was evaluated using the 
isolated mouse spleen. The spleen was removed from male 
mice right after killing the anesthetized animal by cervical 
dislocation. The isolated tissue was incubated in 20 ml cup filled 
with the Krebs-Henseleit solution at the temperature 370C and 
pH 7.4 with constant oxygenation (O2/CO2, 19:1). The initial 
optimal tissues tension was set at 1.0 g. Through the 100 min 
of equilibration tissues were stimulated with noradrenaline 
(0.1 — 10.0 ^M ) three times with washing out until the contractile 
response become constant. Two cumulative concentration- 
response curves to noradrenaline, at an interval of 60 min, were 
established on each tissue both in the presence and absence of 
antagonist. The incubation with antagonists went on for 30 min. 
The experiments were carried out in the constant presence of 
propranolol (1 ^M ) to block ß-adrenoceptors, and minimize 
the involvement of these adrenoceptors in the response to 
noradrenaline.
Influence on a1D-Adrenoceptors: Rat Aorta
Finally, the influence on a 1D-adrenoreceptors was investigated 
using the isolated rat aorta. Rats anesthetized with thiopental 
and killed by cervical dislocation had aorta removed, denuded 
of endothelium and incubated in the Krebs-Henseleit solution 
at the temperature 370C and pH 7.4 with constant oxygenation 
(O2/CO2, 19:1). The aorta rings were maintained at optimal 
tension of 2.0 g. During 3 h  of equilibration tissues were 
stimulated with noradrenaline three times (0.3 ^M ). Two 
cumulative concentration-response curves to noradrenaline, at 
an interval of 60 min, were established on each tissue both 
in the presence and absence of antagonist. The incubation
with antagonists went on for 30 min. The experiments were 
carried out in the constant presence of yohimbine (0.1 ^M ) 
and propranolol (1 ^M ) to block a 2- and ß-adrenoceptors, 
respectively.
Prophylactic Antiarrhythmic Activity in 
Adrenaline-, Barium Chloride-, and 
Calcium Chloride-Induced Arrhythmias
The procedures were performed according to the method 
described by Szekeres and Papp (1975). The heart rate 
disturbances were evoked by the intravenous administration 
of adrenaline (20 ^g/kg), barium chloride (32 and 10 mg/kg) 
or calcium chloride (140 and 25 mg/kg) solution into the 
caudal vein in anesthetized rats (thiopental, 75 mg/kg). The 
studied compounds were administered i.p. 45 min before the 
injection of adrenaline, calcium chloride, or barium  chloride. The 
electrocardiogram (ECG) was recorded during the first 2 min as 
well as in the 5th, 10th, and 15th min after the arrhythmogen 
injection. The criterion of antiarrhythmic activity was the lack of 
extrasystoles and inhibition of cardiac arrhythmia in comparison 
with the control group in adrenaline-induced arrhythmia or the 
progressive disappearance of the arrhythmia and reinstatement 
of the sinus rhythm  in barium  chloride- and calcium chloride- 
induced arrhythmias. The ED5 0  (a dose producing a 50% 
inhibition of ventricular contractions) with 95% confidence 
limits was determined by computer log-probit analysis according 
to Litchfield and Wilcoxon (1949) and Szekeres and Papp (1975). 
The compounds were administered at the dose 10 mg/kg. We 
gradually decreased the dose by half until the disappearance of 
antiarrhythmic activity.
Therapeutic Antiarrhythmic Activity in 
Adrenaline-Induced Arrhythmia
The experiment was performed according to the method 
described by Szekeres and Papp (1968). The arrhythmia 
was evoked by the intravenous administration of adrenaline 
(20 ^g/kg) into the caudal vein in anesthetized rats (thiopental, 
75 mg/kg). The tested compounds were injected i.v. at the peak 
of arrhythmia directly after adrenaline injection, at the ED8 4  
(a dose producing a 84% inhibition of premature ventricular 
contractions established in prophylactic adrenaline-induced 
arrhythmia). The range of doses was 0.325—0.504 mg/kg. The 
ECG was recorded constantly for 5 min as well as in the 10th 
and 15th min of the experiment. The criterion of antiarrhythmic 
activity was the reduction of premature ventricular contractions 
in comparison with the control group (Sapa et al., 2011).
The Effect on Normal Electrocardiogram in 
Rats
The experiment was carried out to exclude the influence of 
tested compounds on normal ECG. The ECG was recorded 
(ASPEL ASCARD B5 apparatus, standard lead II and paper 
speed of 50 mm/s) prior and also 5, 10, 15, 20, 30, 40, 50, and 
60 min after the i.p. administration of tested compounds. The 
influence on QRS complex, PQ interval, heart rate (RR), and QTc 
interval was determined. The QTc was calculated according to the
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Bazzett’s formula: QTc =  Q T ^ R R  (De Clerck et al., 2002). The 
compounds were administered at the ED84 (a dose producing a 
84% inhibition of premature ventricular contractions established 
in prophylactic adrenaline-induced arrhythmia).
Influence on Blood Pressure in 
Normotensive Rats
Normotensive rats were anesthetized with thiopental (75 mg/kg 
ip). The right carotid artery was cannulated with a polyethylene 
tube filled with heparin solution to allow pressure measurements, 
using a Datamax apparatus (Columbus Instruments, USA; 
Kubacka et al., 2013b). The tested compounds were administered 
i.p. after 15 min of stabilization period. The compounds were 
administered at the dose 10 mg/kg. We gradually decreased the 
dose by half until the disappearance of antiarrhythmic activity.
Influence on Blood Vasopressor Response 
in Rats
To verify if the hypotensive activity was a result of a-adrenolytic 
properties, we studied the influence of tested compounds 
on the pressor response to methoxamine (150 ^g/kg) The 
experiment was carried out for all active compounds, which were 
administered (i.v.) to the caudal vein at the lowest hypotensive 
dose (Kubacka et al., 2013b). Pressor response to methoxamine 
injected i.v. was measured before (control) and 5 min after the 
tested compounds. We administered the tested compounds at the 
lowest possible doses, not to lose selectivity for a 1 -adrenoceptors.
Antioxidant Effect—Lipid Peroxidation in 
Rat Brain Homogenate
This experiment was performed according to the method 
described by Yue et al. (1992). The rat brain homogenate 
containing 10 mg tissue/ml was prepared in 0.9% saline. The rates 
of membrane lipid peroxidation were measured by the formation 
of thiobarbituric acid reactive substances (TBARS). Rat brain 
homogenates (1ml) were incubated at 370 C for 5 min with 10 
^ l of a tested compound or vehicle. Lipid peroxidation was 
initiated by the addition of 50 ^ l of 0.5 mM FeCl2 and 50 ^ l of 
2.0 mM ascorbic acid. After 30 min of incubation, the reaction 
was stopped by adding 0.1 ml of 0.2% butylated hydroxytoluene 
(BHT). Thiobarbituric acid reagent was then added and the 
mixture was heated for 15 min in a boiling water bath. Carvedilol 
was used as reference compound. The compounds were tested at 
a concentration of 10—3 M. The TBARs were measured at 532 nm.
Data Analysis
In radioligand binding studies, the obtained data were fitted 
to a one-site curve-fitting equation with Prism 6.0 (GraphPad 
Software), and inhibition constants (Ki) values were estimated 
from the Cheng—Prusoff equation (Cheng and Prusoff, 1973):
Ki =
IC 50
1 +  La- 1 +  Kd
LO-labeled ligand concentration, KD-dissociation constant of 
labeled ligand
In functional bioassays the concentration-response curves 
were analyzed using GraphPad Prism 6.0 software (GraphPad 
Software Inc., San Diego, CA, USA) as previously described 
by Kubacka et al. (2013b). Data are means ±  S.E.M. of 
at least 4 separate experiments. To establish Hill slopes for 
the agonist concentration-response curves and calculate EC5 0  
values, curves were fitted to all the data by non-linear regression. 
The EC5 0  value in the presence and absence of antagonists 
was used to ascertain the concentration ratio (CR). Schild 
analysis was performed. If the slope was not significantly 
different from unity, the relative antagonistic potencies (pA2: 
—log of the concentration of an antagonist that doubles the 
concentration of the agonist needed to elicit the original 
submaximal response obtained in the absence of antagonist) 
were determined by plotting the log (CR-1) against the —log of 
antagonist concentration (Arunlakshana and Schild, 1959).
In case of in vivo experiments the results are presented as 
the means ±  S.E.M. Statistically significant differences between 
groups were calculated using one-way analysis of variance 
(ANOVA) with repeated measurements followed by D unnett’s 
or Bonferroni’s test post-hoc or Student’s t-test. The criterion for 
significance was set at p <  0.05.
Antioxidant activity was expressed as the percentage 
reduction of the sample absorbance during the reaction at 
wavelength 532 nm.
The log-probit method described by Litchfield and Wilcoxon 
(1949) was used to determine median effective doses (ED50— 
doses producing 50% inhibition of premature ventricular 
contractions) and doses producing 84% of the maximal effect 
(ED8 4 ) for compounds in arrhythmia models.
RESULTS 
Affinity for Adrenoceptors
All studied compounds possessed high affinity for a 1- 
adrenoceptors but none of them bound to ß 1 -adrenoceptors 
(Table 1).
Functional Affinity for a 1 A -, a1 B -, and 
a - iD -adrenoceptors
The tested compounds antagonized noradrenaline evoked 
contraction in isolated rat aorta and tail artery, as well 
as mouse spleen, and concentration-dependently, shifted the 
noradrenaline response to the right, w ithout affecting the 
maximum response. The obtained pA2  values with Schild 
slopes not significantly different from unity indicated a 
competitive antagonism at a1A-, a1B-, and a1D-adrenoceptors 
(Tables 2A,B).
HBK-14, HBK-15, HBK-16, HBK-17, and HBK-18 showed 
stronger antagonistic properties at a 1D- than a 1A- or a 1B- 
adrenoceptors. HBK-19 antagonized a 1A-adrenoceptors stronger 
than two other subtypes. All compounds antagonized a 1A- 
adrenoceptors stronger than a 1B-subtype. Among the studied 
compounds the strongest antagonist of a1A-adrenoceptor was 
HBK-19, a 1B-adrenoceptor—HBK-18, and a 1D-adrenoceptor— 
HBK-16.
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The Effect on Normal Electrocardiogram in 
Rats
Table 3 shows the influence of tested compounds on normal ECG 
in rats.
HBK-14 and HBK-15 administered at the dose 6.154 and 
20.218 mg/kg, respectively did not influence the ECG parameters 
throughout the experiment. HBK-16 at the dose 0.363 mg/kg 
did not influence PQ interval, QRS complex or QTc interval 
but it significantly reduced heart rate by 11 — 13%, since the 
40th min of the observation. Similarly, HBK-17 at the dose
0.504 mg/kg significantly decreased heart rate by 9—12%, 20 min 
after administration, without affecting PQ interval, QRS complex 
or QTc interval. HBK-18 at the dose 0.325 mg/kg significantly
TABLE 1 | The affinity of tested compounds for a 1 - and ß1 -adrenoceptors.
Compound Adrenergic receptors K; (nM)
«1 ß1
HBK-14 22.8a n.aa
HBK-15 13.1a n.aa
HBK-16 5.0 n.a.
HBK-17 12.9 n.a.
HBK-18 5.2 n.a.
HBK-19 22.7 n.a.
Phentolamine 18.3 —
Propranolol — 7.1
Carvedilol 2.2b 0.8b
Inhibition constants (K) were calculated according to the equation of Cheng and Prusoff 
(1973). The compounds were tested in three separate experiments in duplicates. n.a.,
compound did not bind to the receptor at the concentration 10~5 M. 
aPytka et al. (2015). 
bPönicke et al. (2002).
reduced the heart rate by 13—23%, since the 15thmin of the 
observation and did not affect PQ interval, QRS complex or 
QTc interval. HBK-19 at the dose 0.444 mg/kg between the 15th 
and 30th min after administration reduced heart rate by 21—22% 
without the influence on PQ interval, QRS complex, or QTc 
interval.
Prophylactic Antiarrhythmic Activity in 
Adrenaline-, Barium Chloride-, and 
Calcium Chloride-Induced Arrhythmias
In anesthetized rats i.v. injection of adrenaline (20 ^g/kg) caused 
atrioventricular disturbances, ventricular and supraventricular 
extrasystoles in 100% of the animals, which led to the death 
of ^70%  of the animals. The studied compounds administered 
45 min (i.p.) prior to adrenaline, decreased the num ber of 
extrasystoles and mortality (Figures 2 , 3, Table 4 ). Table 5 shows 
the ED50 values (doses producing 50% inhibition of premature 
ventricular contractions).
The injection (i.v.) of barium  chloride (32 mg/kg) caused rapid 
ventricular extrasystoles in all animals (100%), which led to the 
death within 3—5 min. Lower dose ofbarium  chloride (10 mg/kg) 
caused ventricular extrasystoles in around 60% ofrats and did not 
lead to the death of animals. We did not observe a reproducible 
negative effect on heart rhythm  when barium  chloride was 
used at the dose 10 mg/kg. None of the tested compounds 
administered (i.p.) 45 min before barium  chloride were active 
in barium chloride-induced model of arrhythmia (data not 
shown).
In anesthetized rats injection (i.v.) of calcium chloride 
(140 mg/kg) caused rapid ventricular fibrillation in all animals 
(100%), which led to death within 3—5 min. The intravenous 
administration of calcium chloride (25 mg/kg) caused ventricular 
fibrillation in all animals, but did not lead to the death of rats.
TABLE 2A | The functional affinities of tested and reference compounds for a 1 -adrenergic receptor subtypes.
Compound Isolated tissues , a 1 -adrenoceptor subtypes , pA2  ±  S .E .M . (slope ±  S.E.M.)
Rat tail artery
«1A
Mouse spleen
«1B
Rat aorta
«1D
HBK-14 7.99 ±  0.09 (0.97 ±  0.15) 7.70 ±  0.08 (1.03 ±  0.03) 8.86 ±  0.06 (1.09 ±  0.10)
HBK-15 7.71 ±  0.07 (1.01 ±  0.18) 7.67 ±  0 .09(0.96 ±  0.01) 8.90 ±  0.09 (1.09 ±  0.09)
HBK-16 8.75 ±  0.03 (1.06 ±  0.08) 8.21 ±  0 .07(1.03 ±  0.12) 9.14 ±  0.03(1.11 ±  0.12)
HBK-17 8.15 ±  0.08 (0.91 ±  0.05) 7.94 ±  0.06 (0.91 ±  0.03) 8.83 ±  0.09(1.01 ±  0.07)
HBK-18 8.49 ±  0.09 (1.10 ±  0.06) 8.35 ±  0.05 (1.03 ±  0.18) 8.92 ±  0.08(1.01 ±  0.05)
HBK-19 8.91 ±  0.09 (0.96 ±  0.05) 8.07 ±  0.07 (1.06 ±  0.05) 8.31 ±  0 .08(1.03 ±  0.09)
Prazosin 8.93 ±  0.03a 9.07 ±  0.09b 8.85 ±  0.09b
Tamsulosin 10.32 ±  0.05c 8.33 ±  0.08d 9.56 ±  0.07d
The functional affinities were determined in the rat tail artery (aiA-adrenoceptor subtype), mouse spleen (aiB-adrenoceptor subtype), rat aorta (a^-adrenoceptor subtype). Noradrenaline 
was used as ai-adrenergic receptor agonist. The highest pÄ2  values for each receptor subtype are in bold font. Antagonist potency of the tested compounds was expressed as pÄ2 ±  
S.E.M. pÄ2  was defined as —log o f the concentration of an antagonist that doubles the concentration of the agonist necessary to elicit the original submaximal response in the absence 
of antagonist. pÄ2  values were obtained from the linear regression of Schild plot (Aruniakshana and Schild, 1959). Each value was the mean ±  S.E.M. o f 4 -8  experimental results. 
aPares-Hip6lito et al. (2006). 
bEltze (1996). 
cJähnichen et al. (2004). 
dEltze et al. (1999).
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None of the tested compounds administered (i.p.) 45 min prior 
to calcium chloride were active in the above model of arrhythmia 
(data not shown).
Therapeutic Antiarrhythmic Activity in 
Adrenaline-Induced Arrhythmia
All tested compounds administered i.v. at the peak of 
adrenaline-induced arrhythmia (20 ^g/kg) reduced the number 
of premature ventricular contractions (Figure 4).
Influence on Blood Pressure in 
Normotensive Rats
Table 6 presents the lowest dose of each tested compound, 
which significantly lowered systolic and diastolic blood pressure 
in rats.
HBK-14 at the dose 0.625 mg/kg, 10 min after injection, 
significantly reduced systolic blood pressure by 5—10%, and 
diastolic blood pressure by 9—14% since the 20th min of 
the observation. HBK-15 at the dose 5.0 mg/kg significantly 
reduced systolic blood pressure by 13—19%, and diastolic blood 
pressure by 13—20%, 5 min after administration. HBK-16 at 
the dose 0.1 mg/kg, 20 min after administration, significantly 
reduced systolic blood pressure by 8—11% and diastolic 
blood pressure by 6—10%. HBK-17 at the dose 0.1 mg/kg 
significantly reduced systolic blood pressure by 8—11% and 
diastolic blood pressure by 10—16%, 20 min after administration. 
HBK-18 at the dose 0.01 mg/kg, from the 20th min of the 
observation, significantly reduced systolic and diastolic blood 
pressure by 23—28 and 16—18%, respectively. HBK-19 at the 
dose 0.625 mg/kg since the 5th min after i.p. administration, 
significantly reduced systolic blood pressure by 5—17%, whereas 
diastolic blood pressure by 9—15% since the 10th min of the 
observation.
Influence on Blood Vasopressor Response 
in Rats
In the control group the increase of blood pressure after 
methoxamine (150 ^g/kg) was ranging from 62.7 ±  10.4 to 94.2 
±  2.7 mmHg. Figure 5 shows that all tested compounds at the 
lowest hypotensive doses, significantly antagonized the pressor 
response to methoxamine.
Influence on Lipid Peroxidation in Rat 
Brain Homogenate
Carvedilol, HBK-16, HBK-17, HBK-18, and HBK-19 inhibited 
lipid peroxidation (Table 7). HBK-14 and HBK-15 were inactive 
in this test.
DISCUSSION
We found that the studied 2-methoxyphenylpiperazine 
derivatives that possessed stronger a1A-adrenolytic properties 
(i.e., HBK-16, HBK-17, HBK-18, and HBK-19) were the most 
active compounds in adrenaline-induced arrhythmia. Their 
antiarrhythmic (but not antioxidant) activity was comparable to 
that of carvedilol. The tested compounds showed hypotensive
TABLE 2B | The affinity of tested compounds for « 1  -adrenergic receptor 
subtypes.
Compound The affinity for « 1 -adrenergic receptor subtypes
HBK-14 a 1D >  a 1A >  a 1B
HBK-15 a 1D >  a 1A >  a 1B
HBK-16 a 1D >  a 1A >  a 1B
HBK-17 a1D >  a1A >  a1B
HBK-18 a1D >  a1A >  a1B
HBK-19 a 1A >  a 1D >  a 1B
The functional affinities were determined in the rat tail artery (a1Ä-adrenoceptor subtype), 
mouse spleen (a 1B-adrenoceptor subtype), rat aorta (a 1D-adrenoceptor subtype).
effect resulting from their a 1-adrenolytic properties. HBK-19 
was the only compound in the group that did not lower blood 
pressure at antiarrhythmic doses.
Scientists reported that 2-methoxyphenylpiperazine 
derivatives often interact with adrenergic receptors (Handzlik 
et al., 2008; Kubacka et al., 2013a; Rapacz et al., 2014, 2015a,b). 
Thus, we evaluated the affinity of the studied compounds for 
a 1-and ß1-adrenoceptors. The radioligand studies revealed that 
HBK-16, HBK-17, HBK-18, and HBK-19 possessed high affinity 
for a 1-, but not ß1-adrenoceptors. This is in agreement with our 
previous experiments on 2-methoxyphenylpiperazine derivatives
i.e., HBK-14 and HBK-15, which showed no affinity for ß1- and 
high affinity for a 1 -adrenoreceptors (Pytka et al., 2015).
Studies proved that cardiac myocytes functionally 
express a 1A- and a 1B-adrenoceptors. O’Connell et al. (2003) 
demonstrated that despite the presence of a1D-adrenoceptors 
mRNA, rodent cardiac myocytes did not express a 1D-subtype 
protein by binding. However, Chalothorn et al. (2003) showed 
that a 1D-adrenoceptors might be expressed in the coronary 
vasculature. Thus, a 1A- and a 1B-adrenoceptors may play 
im portant role in the development of arrhythmias induced 
by catecholamines, while a 1D-subtype in ischemia-induced 
arrhythmias.
Scientists indicated that agents which block 
a 1A-adrenoceptors may have antiarrhythmic potential (Hieble,
2000). Harrison et al. (1998) showed that hearts from transgenic 
rats expressing constitutively active a 1B-adrenoceptors, and 
having 50% reduced a 1A-mRNA levels, were less sensitive to 
ischemia-induced ventricular tachycardia than normal rats. Lee 
and Rosen (1993) proved that the blockade of a 1B receptors 
by chlorethylclonidine increased the amplitude of delayed 
afterdepolarizations induced by calcium and phenylephrine. 
Altogether, these findings suggest that agents, which block 
a1A-adrenoceptors stronger than a1B subtype, may have 
antiarrhythmic potential.
Therefore, we determined the selectivity of studied 
compounds at a 1-adrenoceptor subtypes. Biofunctional 
assays revealed that all compounds competitively blocked 
a 1A, a 1B, and a 1D subtypes. HBK-19 and HBK-16 were the 
strongest a 1A-adrenoceptor antagonists, while HBK-14 and 
HBK-15 were the weakest. Although we did not find highly 
selective compounds, all 2-methoxyphenylpiperazine derivatives 
antagonized a 1A-adrenoceptors stronger than a 1B subtype.
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TABLE 3 | The influence of the tested com pounds on ECG.
Compound Param eters Time of observation (min)
0 5 10 15 20 30 40 50 60
HBK-14 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
366.0 ±  10.8
47.1 ±  1.1
26.1 ±  0.7 
8 5 .8 ± 1 .3
211.7 ±  3.2
369.8 ±  10.0 
4 6 .0 ± 1 .0  
2 5 .8 ± 0 .5  
8 5 .0 ±4 .1  
2 0 9 .2 ± 8 .3
367.0 ±  9.9 
46.3 ±  0.9 
2 7 .6 ± 1 .0  
8 8 .7 ± 1 .9  
214.8 ±  5.0
359.8 ±  9.5 
4 7 .5 ± 1 .3
27.0 ±  0.6
89.0 ±  2.4
212.9 ±  5.7
3 5 8 .4 ± 1 1 .4  
4 6 .3 ± 1 .0  
26.3 ±  0.4 
8 8 .2 ± 2 .9  
212.5 ±  4.6
359.8 ±  9.6 
4 8 .8 ± 1 .9  
26.7 ±  0.9 
8 9 .6 ± 1 .7  
214.1 ±  5.0
3 6 2 .6 ± 1 1 .9  
4 8 .2 ±2 .1  
26.1 ± 0 .4  
8 9 .0 ±2 .1  
214.1 ±  5.2
361.6 ±  12.6 
4 7 .3 ± 1 .6  
2 6 .7 ± 1 .0  
8 7 .9 ± 1 .2  
210.9 ±  5.1
3 64 .6± 1 1 .2
48.4 ±  0.9
27.5 ±  0.7
89.5 ±  2.4 
214.1 ±  4.2
HBK-15 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
353.8 ±  10.2 
4 8 .7 ± 1 .0  
25.7 ±  0.7 
8 7 .3 ± 1 .4  
212.0 ±  5.0
365.4 ±  15.3 
4 8 .4 ± 0 .5  
2 6 .3 ± 0 .9  
8 6 .5 ± 1 .3  
213.6 ±  7.0
350.8 ±  10.5 
4 8 .2 ± 1 .0  
26.1 ±  1.1 
87.2 ±  2.0 
211.3 ±  6.2
333.9 ±  12.4 
46.6 ±  0.9 
2 5 .6 ± 1 .2  
87.5 ±  2.0 
207.1 ±  6.8
3 2 7 .6 ± 2 0 .3  
47.6 ±  0.5 
26.3 ±  0.5 
87.2 ±  0.6 
203.7 ±  7.2
340.1 ±  17.7 
46.1 ±  0.3 
26.4 ±  0.9 
8 6 .7 ±1 .1  
206.4 ±  7.9
339.5 ±  20.4 
46.1 ± 0 .7  
2 8 .0 ± 0 .9  
8 7 .0 ± 1 .5  
2 0 6 .5 ± 6 .6
350.1 ±  17.9 
47.5 ±  0.7 
26.1 ±  1.2 
88.2 ±  0.8 
212.7 ±  6.9
351.8 ±  15.0 
4 8 .0 ±1 .1  
26.3 ±  0.5 
88.5 ±  2.2
213.9 ±  7.2
HBK-16 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
329.6 ±  9.8 
6 4 .4 ±1 .1  
21.7 ±  2.2 
51.4 ±  3.5 
120.5 ±  8.7
331.4 ±  12.5 
6 3 .7 ±1 .1  
21.7 ±  2.2 
51.2 ±  3.5 
120.7 ±  9.7
330.1 ±  12.4
63.6 ±  0.9
21.7 ±  2.2 
51.2 ±  3.3
120.2 ±  8.8
319.4 ±  10.3 
6 3 .9 ±1 .1  
21.7 ±  2.2 
50.1 ±  3.6 
115.8 ±  9.6
310.6 ±  9.8 
65.1 ± 1 .2  
21.7 ±  2.2 
51.4 ±  3.1 
117.3 ±  8.7
3 0 2 .8 ± 1 1 .0
6 4 .4 ±1 .1
21.7 ±  2.2
52.7 ±  3.7 
119.0 ±  10.3
294.1 ±  12.2a 291.4 ±  13.0b 288.0 ±  13.8b 
65.9 ±  0.8 67.3 ±  1.6 68.2 ±  0.9 
21.7 ±  2.2 22.0 ±  2.1 22.3 ±  2.0 
53.5 ±  2.8 54.7 ±  2.8 55.5 ±  2.4 
118.9 ±  8.4 121.1 ±  8.7 122.0 ±  7.7
HBK-17 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
365.2 ±  15.0 
66.5 ±  3.7 
2 3 .3 ± 1 .8  
55.2 ±  2.3 
135.8 ±  5.3
359.4 ±  16.6 
6 5 .0 ± 3 .3  
2 3 .3 ± 1 .4  
5 5 .3 ± 0 .9  
135.2 ±  3.3
348.7 ±  15.0 
64.3 ±  3.4 
2 3 .0 ± 1 .7  
5 5 .7 ±1 .1  
134.1 ±  3.1
341.1 ±  13.4 
65.6 ±  3.7
23.3 ±  2.0
57.4 ±  0.8 
136.5 ±  2.3
333.5 ±  13.3b 
65.9 ±  3.4 
2 2 .7 ± 1 .8  
5 7 .7 ± 1 .8
135.6 ±  3.5
327.4 ±  11.8c
67.7 ±  4.0
22.7 ±  2.0 
6 0 .3 ±1 .1
140.7 ±  3.7
333.0 ±  10.6b 
6 7 .0 ± 3 .2  
2 3 .0 ± 1 .7  
61.3 ±  1.6 
144.3 ±  5.0
323.8 ±  14.1 c
67.4 ±  3.5 
2 3 .3 ± 1 .4
60.4 ±  2.0 
140.2 ±  5.4
320.9 ±  13.4c 
67.6 ±  3.3 
2 3 .0 ± 1 .7  
61.5 ±  2.3 
142.0 ±  5.0
HBK-18 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
328.0 ±  7.4 
61.3 ±  4.6 
28.1 ±  3.1 
73.9 ±  6.2 
172.4 ±  13.5
3 0 6 .9 ± 9 .0  
61.5 ±  6.3 
3 0 .4 ± 3 .2  
7 7 .0 ± 7 .0  
174.2 ±  16.3
298.7 ±  8.9 
57.4 ±  4.2 
30.8 ±  3.6 
77.7 ±  4.9 
173.4 ±  11.7
284.7 ±  7.6a 
5 5 .8 ± 1 .6
27.0 ±  2.9
76.1 ±  5.8 
166.4 ±  14.5
273.9 ±  8.0b 
51.9 ±  3.8 
29.1 ± 2 .7  
7 7 .9 ± 4 .2
166.9 ±  11.1
267.4 ±  17.5c 
56.9 ±  3.5 
28.5 ±  2.8 
75.3 ±  3.2 
159.0 ±  9.7
260.3 ±  22.8c 
5 7 .4 ±3 .1  
2 8 .6 ± 2 .8  
7 6 .9 ± 4 .9
160.4 ±  14.4
258.9 ±  25.4c
59.0 ±  3.8 
27.6 ±  3.0
76.0 ±  2.9 
157.2 ±  9.9
252.3 ±  25.1c
59.6 ±  4.7 
30.9 ±  3.8
76.7 ±  3.5 
157.1 ±  12.0
HBK-19 Beats/min 
PQ (ms) 
QRS (ms) 
QT (ms) 
QTc (ms)
355.3 ±  19.7 
56.7 ±  0.7 
3 5 .7 ± 1 .0  
76.4 ±  8.2 
186.9 ±  24.6
3 4 9 .7 ± 2 5 .3  
5 6 .6 ± 0 .0  
3 4 .7 ± 1 .6  
7 6 .9 ±1 .1  
185.5 ±  9.5
339.1 ±  21.0
56.0 ±  0.0
34.0 ±  0.3 
77.5 ±  0.5
184.2 ±  6.9
280.1 ±  1.1c 
5 8 .2 ± 1 .8  
3 2 .0 ± 1 .2  
82.2 ±  2.2 
177.6 ±  4.4
2 7 7 .2 ± 5 .0 c 
60.1 ± 1 .3  
32.7 ±  0.4 
8 4 .3 ±1 .1  
181.1 ±  4.1
278.2 ±  6.7c
60.1 ±  1.7 
34.3 ±  0.2
82.2 ±  0.4 
177.0 ±  3.0
332.8 ±  18.9 
5 9 .3 ± 0 .7  
3 2 .0 ±3 .1  
81.5 ±  2.5 
192.2 ±  11.2
396.8 ±  31.8 
55.1 ±  0.3 
3 6 .0 ± 1 .5  
76.5 ±  0.5 
196.2 ±  6.9
398.0 ±  32.4 
5 6 .3 ±1 .1  
3 0 .3 ±1 .1  
80.2 ±  0.4 
206.3 ±  9.6
Rats were anesthetized intraperitoneally (i.p.) with thiopental (75 mg/kg). The compounds were administered (i.p.) at the EÜ84 obtained in prophylactic adrenaline-induced arrhythmia 
i.e., 6.154 mg/kg (HBK-14), 20.218 mg/kg (HBK-15), 0.363mg/kg (HBK-16), 0.504 mg/kg (HBK-17), 0.325 mg/kg (HBK-18), 0.444 mg/kg (HBK-19). The data are expressed as mean 
±  S.E.M. Statistical analysis: one-way ÄNOVÄ with repeated measurements, Dunnet post-hoc test, 
ap  < 0.05,
bp  < 0.01,
cp  < 0.001 vs. initial values. n =  4-6  rats per group.
HBK-19 showed the greatest difference in pA2 values—it 
blocked a 1A-adrenoceptors around seven-fold stronger than a 1B 
subtype.
Since all studied compounds blocked a 1A- and a 1B- 
adrenoceptors, we decided to examine their antiarrhythmic 
activity. We also investigated whether antiarrhythmic activity 
depended on the strength of a 1A-adrenoceptor blockade or the 
differences between pA2 values for a 1A- and a 1B-adrenoceptors. 
To determine antiarrhythmic effect, we used three models of 
arrhythmia i.e., adrenaline-, barium  chloride-, and calcium 
chloride-induced.
All compounds showed antiarrhythmic activity in adrenaline- 
induced model of arrhythmia, and reduced mortality of rats. 
HBK-18 possessed the strongest prophylactic antiarrhythmic 
properties, but ED50 values for HBK-16, HBK-17, and HBK-19 
were also very low. Except for HBK-14 and HBK-15, prophylactic 
antiarrhythmic activities of compounds in adrenaline-induced 
arrhythmia were comparable to that of carvedilol (reference 
drug). We think that the weak antiarrhythmic activity of HBK 14 
and HBK 15 may be due to their weaker a 1 -adrenolytic properties 
(see Table 2), which are crucial for antiarrhythmic effect in the 
applied model of arrhythmia. Since the compounds used in the
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FIGURE 2 | Representative ECGs after treatm ent with adrenaline and/or HBK-16, HBK-17, HBK-18, and HBK-19 in rats. (A) Normal reading (Control). (B) 
Arrhythmia control—adrenaline (20 ^g /kg , i.v.). (C) Adrenaline-induced arrhythmia (20 ^g /kg , i.v.)+HBK-16 (0.3 mg/kg, i.v. injection 45 min prior to adrenaline). (D) 
Adrenaline-induced arrhythmia (20 ^g /kg , i.v.)+HBK-17 (0.3 mg/kg, i.v. injection 45 min prior to adrenaline). (E) Adrenaline-induced arrhythmia (20 ^g /kg , i.v.)+HBK-18 
(0.3 mg/kg, i.v. injection 45 min prior to adrenaline). (F) Adrenaline-induced arrhythmia (20 ^g /kg , i.v.)+HBK-19 (0.3 mg/kg, i.v. injection 45 min prior to adrenaline).
Adrenaline HBK-14 HBK-15 HBK-16 HBK-17 HBK-18 HBK-19
FIGURE 3 | The effect of adrenaline and studied compounds on m ortality of rats in prophylactic adrenaline-induced arrhythmia. Rats were anesthetized 
with intraperitoneal (i.p.) injection of thiopental (75 mg/kg). The tested compounds were administered (i.p.) 45 min before the experiment. The observation was carried 
out for 15 min after the intravenous injection of adrenaline (20 ^g/kg). n =  5 —6 animals per group.
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TABLE 4 | The antiarrhythmic activity of 2-m ethoxy phenylpiperazine  
derivatives in prophylactic model of adrenaline induced arrhythmia.
Compound Dose Extrasystoles Bigeminy Bradycardia Blocks
(mg/kg) (%) (%) (%) (%)
Adrenaline - 66.7 33.3 66.7 50.0
HBK-14 2.5 100.0 50.0 83.3 83.3
5 50.0 33.3 50.0 33.3
10 16.7 16.7 50.0 33.3
HBK-15 2.5 66.7 33.3 66.7 66.7
5 50.0 16.7 66.7 50.0
10 33.3 16.7 50.0 33.3
HBK-16 0.1 83.3 33.3 66.7 50.0
0.2 33.3 16.7 50.0 33.3
0.3 16.7 - 33.3 16.7
HBK-17 0.1 66.7 50.0 67.7 67.7
0.2 50.0 33.3 50.0 33.3
0.3 16.7 16.7 33.3 16.7
HBK-18 0.1 83.3 50.0 66.7 66.7
0.2 50.0 16.7 50.0 33.0
0.3 16.7 12.0 16.3 16.3
HBK-19 0.1 66.7 33.3 66.7 50.0
0.2 50.0 16.7 33.3 33.3
0.3 16.7 - 16.7 16.7
Rats were anesthetized with intraperitoneal (i.p.) injection of thiopental (75 mg/kg). The 
tested compounds were administered (i.p.) 45 min before the experiment. The observation 
was carried out for 15min after the intravenous injection of adrenaline (20 pg/kg) i.e., 
during the first 2 min, in the 5, 10, and 15th min. n =  5—6 animals per group.
TABLE 5 | Prophylactic antiarrhythmic activities of tested compounds and 
carvedilol in adrenaline-induced arrhythmia.
Compound ED50(mg/kg)
HBK-14 3.88 (2.68—5.61)
HBK-15 4.80 (2.32—9.93)
HBK-16 0.20 (0.10—0.39)
HBK-17 0.20 (0.12—0.35)
HBK-18 0 .18 (0 .11—0.29)
HBK-19 0.21 (0.13—0.34)
Carvedilol 0.36 (0.16—0.80)
Rats were anesthetized with intraperitoneal (i.p.) injection of thiopental (75 mg/kg). The 
tested compounds were administered (i.p.) 45 min before the experiment. The observation 
was carried out for 15min after the intravenous injection of adrenaline (20 pg/kg) i.e., 
during the first 2 min, in the 5, 10, and 15th min. The ED50 values with confidence limits 
were calculated according to the methods described by Litchfield and Wilcoxon (1949) 
Each value was obtained from three experimental groups. n =  5—6 animals per group.
experiments did not present potent selectivity toward different 
subtypes of a 1—adrenoceptors, we cannot definitely conclude 
which receptor subtype should be primarily blocked to achieve 
antiarrhythmic effect. Although, HBK-19 showed the greatest
FIGURE 4 | Therapeutic antiarrhythmic activities of tested compounds 
in adrenaline-induced arrhythmia. Rats were anesthetized with 
intraperitoneal injection of thiopental (75 mg/kg). The tested compounds were 
administered intravenously (i.v.) at the ED84 obtained in prophylactic 
adrenaline-induced arrhythmia i.e., 0 .363mg/kg (HBK-16), 0 .504mg/kg 
(HBK-17), 0.325 mg/kg (HBK-18), 0.444 mg/kg (HBK-19), 0.979 mg/kg 
(carvedilol). Data are reported as means ±  S.E.M. Statistical analysis: 
Student’s t-test; **p <  0.01, ***p <  0.001. n =  5 —6 animals per group.
difference in pA2 values for the a 1A- and a 1B receptor subtypes, 
it did not possess the strongest antiarrhythmic properties. 
Similarly, according to the studies performed by Koshimizu 
et al. (2004), the pA2 value for a 1A— adrenoceptor subtype for 
carvedilol was 9.0, whereas for a 1B—adrenoceptor was 10.0. 
Carvedilol showed comparable properties in adrenaline-induced 
arrhythmia model. Thus, we claim that the potent blockade of 
a 1A-receptor subtype is essential to attenuate adrenaline-induced 
arrhythmia, but the role of a 1B-adrenoceptor blockade needs 
further studies. Carvedilol is a potent ß1- and a 1-adrenoceptors 
blocker with antioxidant activity. Surprisingly, despite the 
fact that carvedilol blocked both ß1- and a 1-adrenoceptors, 
and the studied compounds only a 1-adrenoceptors, their 
antiarrhythmic effect was comparable. Therefore, we suggest 
that this may indicate more important role of a 1- than 
ß1-adrenoceptors blockade in adrenaline-induced arrhythmia 
model.
Arrhythmia models induced by calcium or sodium chloride 
are associated with the changes in intracellular ion concentration. 
These changes are ion channel dependent, and their dynamics 
and amplitude are high. In arrhythmias induced by adrenaline, 
the stimulation of adrenergic receptors also leads to ion level 
changes (primarily Ca2+ ), but these changes are not as rapid. 
Their amplitude and dynamics are much lower than the above. 
None of the compounds showed activity in barium chloride- or 
calcium chloride-induced arrhythmias. Therefore, we can assume 
that the blockade of sodium or calcium channels was not the 
predominant mechanism of antiarrhythmic effect of the studied 
compounds.
We decided to test therapeutic antiarrhythmic potential of 
the most active compounds (i.e., HBK-16, HBK-17, HBK-18,
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TABLE 6 | The hypotensive activity of 2-methoxyphenylpiperazine derivatives in normotensive rats.
Compound Dose (mg/kg) Pressure Time of observation (min)
Control 5 10 20 30 40 50 60
HBK-14 0.625 Systolic 138.3 ±  6.8 135.2 ±  7.3 131.2 ±  6.8c 127.3 ±  6.6c 125.3 ±  7.0c 124.2 ±  7.0c 127.3 ±  6.3c 128.2 ±  5.4c
Diastolic 106.7 ±  4.3 105.2 ±  6.1 103.0 ±  5.8 97.3 ±  6.0c 95.2 ±  6.1c 9 2 .3 ± 6 .2 c 94.0 ±  5.8c 98.0 ±  5.1c
HBK-15 5.0 Systolic 139.0 ±  2.7 121.2 ±  4.8c 116.3 ±  6.0c 112.0 ±  5.5c 112.2 ±  4.2c 112.5 ±  4.4c 113.2 ±  3.7c 117.3 ±  3.0c
Diastolic 110.3 ±  2.2 96.3 ±  3.7c 92.0 ±  4.3c 88.5 ±  3.5c 88.3 ±  2.9c 91.0 ±  3.2c 90.2 ±  2.7c 93.0 ±  1.2c
HBK-16 0.1 Systolic 124.7 ±  3.1 123.2 ±  3.3 121.2 ±  3.2 114.8 ±  2.0b 113.0 ±  2.4c 110.3 ±  2.1c 110.8 ±  2.0b 110.7 ±  1.9c
Diastolic 97.0 ±  4.3 9 5 .0 ±5 .1 93.7 ±  5.1 91.3 ±  5.0b 89.8 ±  5.2a 87.7 ±  4.7b 88.0 ±  4.3c 87.7 ±  4.6b
HBK-17 0.1 Systolic 136.8 ±  3.7 132.7 ±  4.8 130.5 ±  4.7 125.5 ±  4.9b 124.2 ±  4.4b 121.7 ±  3.9b 121.5 ±  3.4a 121.2 ±  3.9b
Diastolic 110.7 ±  4.6 108.2 ±  5.2 105.8 ±  4.3 99.3 ±  4.7a 96.8 ±  4.0b 94.0 ±  3.7b 93.3 ±  4.0b 94.5 ±  4.3b
HBK-18 0.01 Systolic 125.7 ±  8.2 117.7 ±  9.1 112.7 ±  7.7 96.5 ±  8.9b 93.8 ±  8.7c 91.8 ±  10.0b 90.7 ±  8.6b 90.2 ±  9.2a
Diastolic 94.3 ±  6.4 9 0 .7 ±7 .1 85.5 ±  7.5 79.5 ±  7.8a 78.3 ±  7.2a 78.8 ±  7.0b 78.7 ±  5.6c 77.5 ±  6.0b
HBK-19 0.625 Systolic 127.0 ±  4.0 121.0 ±  4.0b 116.0 ±  3.5c 111.5 ±  3.2c 110.0 ±  2.3c 107.5 ±  3.2c 106.0 ±  3.5c 106.0 ±  4.0c
Diastolic 98.0 ±  4.6 9 4 .5 ± 2 .6 87.5 ±  0.4c 89.0 ±  2.3b 87.0 ±  2.9c 84.5 ±  1.4c 83.5 ±  1.4c 84.0 ±  0.6c
Rats were anesthetized intraperitoneally (i.p.) with thiopental (75 mg/kg). The compounds were administered (i.p.). The results present the lowest hypotensive dose. The data are the 
means o f six experiments ±  S.E.M. Statistical analysis: one-way ÄNOVÄ test with repeated measurements, Dunnet post-hoc test. 
a p  < 0.05,
bp  < 0.01,
cp  < 0.001 vs. control values. n =  6 rats per group.
and HBK-19) in adrenaline-induced model of arrhythmia. The 
studied compounds restored normal heart rhythm  administered 
at the peak of arrhythmia, but the strongest therapeutic 
antiarrhythmic activity showed HBK-18. The results of this 
experiments correlate with the results obtained in prophylactic 
adrenaline-induced arrhythmia model.
Antiarrhythmic agents have proarrhythmic potential, thus we 
evaluated the influence of studied compounds on normal ECG 
in rats. Only HBK-14 and HBK-15 did not influence ECG at 
ED8 4  obtained in prophylactic adrenaline-induced arrhythmia 
model. The rest of compounds significantly decreased heart 
rate. Williamson et al. (1994) proved that stimulation of a 1A- 
adrenoceptors resulted in positive chronotropic effect. This 
suggests that the decrease in heart rate observed after treatment 
with HBK-16, HBK-17, HBK-18, and HBK-19 was a result of a 1A 
receptor blockade.
The QT interval represents electrical depolarization 
and repolarization of ventricles. The prolongation of QT 
interval indicates the potential of a drug to cause ventricular 
tachyarrhythmias like torsades de pointes. The QTc adjusts 
the QT interval for heart rate extremes. In this study we used 
Bazett’s equation to calculate QTc. Nevertheless, we need to 
point out that even though Bazett’s formula is very often used 
for QT correction, it has many limitations (e.g., over- and 
under-correction of high or low heart rhythms). Rodents’ heart 
rate values can be several times higher than those observed 
in humans (Kmecova and Klimas, 2010). Since heart rhythm 
significantly influences QTc, this might be the reason for the 
observed differences in baseline QTc in our experiments. We 
showed that none of the compounds affected QTc at ED8 4 ,
therefore we can assume that they did not have proarrhythmic 
potential at antiarrhythmic doses.
Our findings are in agreement with the results obtained 
by other researchers, showing that phenylpiperazine derivatives 
possessed a 1-adrenolytic properties, as well as prophylactic 
and/or therapeutic activity in adrenaline-induced arrhythmia 
(Dylag et al., 2004; Handzlik et al., 2012; Kubacka et al., 2013a,b).
When discussing adrenaline-induced arrhythmias we could 
neglect the role of a 1D-adrenoceptors, since their blockade 
should not have a direct influence on cardiac myocytes. 
Nevertheless, in animal studies on drug candidates, we cannot 
entirely ignore the role of a 1D-subtype. a 1D-Adrenoceptors 
blockade in blood vessels might significantly lower blood 
pressure, which due to the baroreflex might increase heart rate, 
and contribute to arrhythmia.
Since all studied compounds blocked a 1D-adrenoceptor, and 
these receptors among others regulate blood pressure, we 
evaluated their influence on blood pressure in rats. All tested 
compounds showed hypotensive properties. HBK-18 showed 
the strongest hypotensive activity, while HBK-15 the weakest. 
Interestingly, the results of this experiment did not correlate with 
the functional bioassays, where the strongest a 1D-adrenoceptor 
blocking properties showed HBK-16. We suspect that this may 
be due to the differences in receptor binding dynamics, but this 
issue would require further experiments. Regarding the case of 
HBK-19, the lowest dose that reduced blood pressure was around 
three-fold higher than ED 5 0  value in prophylactic adrenaline- 
induced arrhythmia. For antiarrhythmic drugs, hypotensive 
activity is not desirable, since a 1-adrenoceptor blockers acting 
in the periphery, may induce reflex tachycardia, and contribute
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FIGURE 5 | The effect of tested compounds on the blood pressure 
response to m ethoxam ine. Rats were anesthetized with intraperitoneal 
injection of thiopental (75 mg/kg). The studied compounds were administered 
intravenously (i.v.), at the lowest hypotensive doses i.e., 0.625 mg/kg 
(HBK-14), 5.0 mg/kg (HBK-15), 0.1 mg/kg (HBK-16), 0.1 mg/kg (HBK-17),
0.01 mg/kg (HBK-18), 0.625 mg/kg (HBK-19). Methoxamine (MET) was 
administered at the dose 150 ^g /kg  (i.v.). All values represent means ±  S.E.M. 
Statistical analysis: Student’s t-test; *p <  0.05, **p <  0.01, compared to the 
initial maximal response (obtained before the administration of tested 
compounds). n =  5 —6 animals per group.
TABLE 7 | The influence of the tested compounds on lipid peroxidation in 
rat brain hom ogenate—antioxidant effect.
Compound Absorbance % reduction of absorbance
(% antioxidant activity)
HBK-14 0.939 ±  0.007 —4.10
HBK-15 0.891 ±  0.008 1.22
HBK-16 0.752 ±  0.007 16.63
HBK-17 0.773 ±  0.009 14.30
HBK-18 0.781 ±  0.004 13.41
HBK-19 0.698 ±  0.007 22.62
Carvedilol 0.094 ±  0.002 89.58
The rates of membrane lipid peroxidation were measured using rat brain homogenate by 
the formation ofthiobarbituric acid reactive substances (TBÄRs). The studied compounds 
were tested at a concentration of 10—3 M. The TBÄRs were measured at 532 nm.
to cardiac arrhythmias. In our opinion, the lack of hypotensive 
properties at antiarrhythmic doses makes HBK-19 the most 
interesting compound in the studied group. Our results suggest 
that the receptor profile of HBK 19 (the highest affinity for a 1A 
and the lowest for a 1D) is the most beneficial in preventing 
adrenaline-induced arrhythmia. Interestingly, this suggests that 
in in vivo conditions the selectivity between a 1A and a 1D is 
much more important in achieving the optimal profile of a 1- 
adrenolytics acting as antiarrhythmic agents, than the selectivity 
between a 1A and a 1B.
In order to prove that hypotensive properties of tested 
compounds were a result of their a  1-adrenolytic properties, 
we performed the experiments with methoxamine (selective 
a 1-adrenoceptor agonist). Drugs that selectively block a 1- 
adrenergic receptors significantly inhibit pressor response to 
methoxamine. All studied compounds blocked the effect caused
by methoxamine, thus we concluded that their hypotensive 
activity was due to a  1-adrenolytic properties.
Oxidative stress plays an important role in arrhythmias 
(Dudek et al., 2014; Sovari, 2016). Reactive oxygen species 
(ROS) prolong action potential duration, induce early 
afterdepolarizations, and delayed afterdepolarizations in rats 
and guinea-pigs (Beresewicz and Horackova, 1991). Scientists 
indicated that oxidative stress activated Ca2+/CaM -dependent 
kinase II (CaMKII), and consequently caused arrhythmias 
(Xie et al., 2009). Rabbits with cardiac hypertrophy pretreated 
with CaMKII inhibitor were less likely to develop ventricular 
arrhythmias (Ke et al., 2007). Kirshenbaum et al. (1990) showed 
that vitamin E (antioxidant) protected rats with chronic heart 
hypertrophy against adrenaline-induced arrhythmias. This 
suggests that oxidative stress plays role in adrenaline-induced 
arrhythmias.
Given the significant antiarrhythmic effect of the 
studied compounds, we decided to investigate whether 2- 
methoxyphenylpiperazine derivatives possess additional 
antioxidant activity. Strong antioxidant activity might have 
contributed to their antiarrhythmic effect. This would 
explain their significant effect in adrenaline-induced model 
of arrhythmia. Our experiments showed that among all studied 
compounds only HBK-16, HBK-17, HBK-18, and HBK-19 
weakly inhibited lipid peroxidation. The effect elicited by 
HBK-19 was the strongest in the group. However, its activity 
was around eight-fold weaker than the effect caused by 
carvedilol. Although HBK-16, HBK-17, HBK-18, and HBK-19 
possessed weaker antioxidant properties than carvedilol, they 
showed stronger antiarrhythmic activity. This confirms that 
in adrenaline-induced arrhythmia model, the blockade of 
a 1-adrenoceptors is more important for antiarrhythmic activity 
than antioxidant properties of the compound. Moreover, our 
findings suggest that antiarrhythmic properties of studied 
compounds resulted predominantly from a  1-adrenolytic 
properties.
The levels of cardiac a 1-adrenoceptor are around 10-fold 
higher in rats than in humans. This may suggest that the 
role of a 1-adrenoceptor blockade in arrhythmia is not as 
significant in humans. Interestingly, despite lower expression 
of a 1 -adrenoceptors in human heart, scientists proved that 
they play a significant role in arrhythmias (Furushima et al.,
2001). Kurtzwald-Josefson et al. (2014) identified a contribution 
of a-adrenergic pathway to pathogenesis of catecholamine- 
induced arrhythmia, and suggested a-blockade as an effective 
therapy in the murine model of catecholaminergic polymorphic 
ventricular tachycardia. The Authors suggested a-adrenolytics 
as an alternative treatment in humans resistant to ß-blockers. 
Thus, it would be reasonable to keep searching for antiarrhythmic 
agents among a 1-adrenolytics.
Since structural similarity of studied compounds reduces 
the likelihood of various mechanisms of action, in future 
studies we plan to investigate another set of structurally similar 
2-methoxyphenylpiperazine derivatives with higher selectivity 
toward a 1A-adrenoceptor subtype. This might give more insight 
into the role of a 1A-adrenoceptor subtype in antiarrhythmic 
effect.
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In conclusion, the studied 2-methoxyphenylpiperazine 
derivatives possessed high affinity for a 1-adrenoceptors and 
competitively antagonized a 1A, a 1B, and a 1D receptor subtypes. 
The compounds that possessed stronger a 1A-adrenolytic 
properties (i.e., HBK-16, HBK-17, HBK-18, and HBK-19) 
were the most active compounds in adrenaline-induced 
arrhythmia. We suggest that their antiarrhythmic activity results 
predominantly from strong a 1A-adrenolytic properties.
AUTHOR CONTRIBUTIONS
Conceived and designed the experiments: KP, SM, JS, BF. 
Performed the experiments: KP, SM, KL, EŻ, MK, AS, AD, 
JŚniecikowska, MŻ. Analyzed the data: KP, SM, KL, EŻ, AO, AG,
REFERENCES
Arunlakshana, O., and Schild, H. O. (1959). Some quantitative uses of drug 
antagonists. Br. J. Pharmacol. Chemother. 14, 48-58.
Beresewicz, A., and Horackova, M. (1991). Alterations in electrical and contractile 
behavior of isolated cardiomyocytes by hydrogen peroxide: possible ionic 
mechanisms. J. Mol. Cell. Cardiol. 23, 899-918.
Chalothorn, D., M cCune, D. F., Edelmann, S. E., Tobita, K., Keller, B. B., Lasley, R. 
D., et al. (2003). Differential cardiovascular regulatory activities of the alpha 1B- 
and alpha 1D-adrenoceptor subtypes. J. Pharmacol. Exp. Ther. 305, 1045-1053. 
doi: 10.1124/jpet. 102.048553 
Cheng, Y., and Prusoff, W. H. (1973). Relationship between the inhibition constant 
(K1) and the concentration of inhibitor which causes 50 per cent inhibition 
(I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
De Clerck, F., Van de Water, A., D’Aubioul, J., Lu, H. R., van Rossem, K., 
Herm ans, A., et al. (2002). In  vivo m easurem ent of QT prolongation, dispersion 
and arrhythmogenesis: application to the preclinical cardiovascular safety 
pharmacology of a new  chemical entity. Fundam. Clin. Pharmacol. 16,125-140. 
doi: 10.1046/j.1472-8206.2002.00081.x 
Deo, R., and Albert, C. M. (2012). Epidemiology and genetics of sudden 
cardiac death. Circulation 125, 620-637. doi: 10.1161/CIRCULATIONAHA. 
111.023838
Dudek, M., Knutelska, J., Bednarski, M., Nowinski, L., Żygm unt, M., Bilska- 
Wilkosz, A., et al. (2014). Alpha lipoic acid protects the heart against myocardial 
post ischemia-reperfusion arrhythm ias via KATP channel activation in isolated 
ra t hearts. Pharmacol. Rep. 66, 499-504. doi: 10.1016/j.pharep.2013.11.001 
Dylag, T., Żygm unt, M., Maciag, D., Handzlik, J., Bednarski, M., Filipek, 
B., et al. (2004). Synthesis and evaluation of in vivo activity of 
diphenylhydantoin basic derivatives. Eur. J. Med. Chem. 39, 1013-1027. 
doi: 10.1016/j.ejmech.2004.05.008 
Eltze, M. (1996). Functional evidence for an alpha 1B-adrenoceptor mediating 
contraction of the mouse spleen. Eur. J. Pharmacol. 311, 187-198.
Eltze, M., König, H., Ullrich, B., and Grebe, T. (1999). Buspirone functionally 
discriminates tissues endowed with alpha1-adrenoceptor subtypes A, B, D and 
L. Eur. J. Pharmacol. 378, 69-83.
Escobar, A. L., Perez, C. G., Reyes, M. E., Lucero, S. G., Kornyeyev, D., Mejia- 
Alvarez, R., et al. (2012). Role of inositol 1,4,5-trisphosphate in the regulation 
of ventricular C a(2+) signaling in intact mouse heart. J. Mol. Cell. Cardiol. 53, 
768-779. doi: 10.1016/j.yjmcc.2012.08.019 
Furushima, H., Chinushi, M., W ashizuka, T., and Aizawa, Y. (2001). Role of 
alpha1-blockade in congenital long QT syndrome: investigation by exercise 
stress test. Jpn. Circ.J. 65, 654-658. doi: 10.1253/jcj.65.654 
Handzlik, J., Bajda, M., Żygm unt, M., Maciag, D., Dybała, M., Bednarski, M., 
et al. (2012). Antiarrhythm ic properties of phenylpiperazine derivatives of 
phenytoin w ith a1-adrenoceptor affinities. Bioorg. Med. Chem. 20, 2290-2303. 
doi: 10.1016/j.bmc.2012.02.009 
Handzlik, J., Maciag, D., Kubacka, M., Mogilski, S., Filipek, B., Stadnicka, K., et al. 
(2008). Synthesis, a1-adrenoceptor antagonist activity, and SAR study of novel
JSmieja. Contributed reagents/materials/analysis tools: AW, HM. 
W rote the paper: KP, SM, AO, KL, EŻ, MK.
FUNDING
This study was supported by Jagiellonian University grants 
number K/DSC/000040 and K/DSC/001955. This work was 
partially supported by NCN grant DEC- 2013/11/B/ST7/01713 
and Silesian University BK grant 227/RAu1/2015/1.
ACKNOWLEDGMENTS
We wish to thank Agnieszka Niedbał and Teresa D obrut for their 
technical assistance.
arylpiperazine derivatives of phenytoin. Bioorg. Med. Chem. 16,5982-5998. doi: 
10.1016/j.bmc.2008.04.058 
Harrison, S. N., Autelitano, D. J., W ang, B.-H., Milano, C., Du, X.-J., and 
W oodcock, E. A. (1998). Reduced reperfusion-induced ins(1,4,5)P3 generation 
and arrhythm ias in hearts expressing constitutively active a1b-adrenergic 
receptors. Circ. Res. 83, 1232-1240.
Hieble, J. P. (2000). Adrenoceptor subclassification: an approach to improved 
cardiovascular therapeutics. Pharm. Acta Helv. 74, 163-171. doi:
10.1016/S0031-6865(99)00030-8 
Jähnichen, S., Eltze, M., and Pertz, H. H. (2004). Evidence that alpha(1B)- 
adrenoceptors are involved in noradrenaline-induced contractions of ra t tail 
artery. Eur. J. Pharmacol. 488, 157-167. doi: 10.1016/j.ejphar.2004.02.020 
Ke, J., Żhang, C., Ma, Y., Liu, J., Żhang, Q., Liu, N., et al. (2007). [The effects 
of calmodulin kinase II inhibitor on ventricular arrhythm ias in rabbits with 
cardiac hypertrophy]. Zhonghua X in  X ue Guan Bing Za Zhi 35, 33-36. doi: 
10.3760/j:issn:0253-3758.2007.01.008 
K irshenbaum, L. A., Gupta, M., Thomas, T. P., and Singal, P. K. (1990). 
A ntioxidant protection against adrenaline-induced arrhythm ias in rats with 
chronic heart hypertrophy. Can. J. Cardiol. 6, 71-74.
Kmecova, J., and Klimas, J. (2010). H eart rate correction ofthe  QT duration in rats.
Eur. J. Pharmacol. 641, 187-192. doi: 10.1016/j.ejphar.2010.05.038 
Koshimizu, T.-A., Tsujimoto, G., Hirasawa, A., Kitagawa, Y., and Tanoue, A. 
(2004). Carvedilol selectively inhibits oscillatory intracellular calcium changes 
evoked by hum an alpha1D- and alpha1B-adrenergic receptors. Cardiovasc. Res. 
63, 662-672. doi: 10.1016/j.cardiores.2004.05.014 
Kubacka, M., Mogilski, S., Filipek, B., and M arona, H. (2013a). A ntiarrhythm ic 
properties of some 1,4-disubstituted piperazine derivatives with a1- 
adrenoceptor affinities. Eur. J. Pharmacol. 720, 237-246. doi: 10.1016/ 
j.ejphar.2013.10.021
Kubacka, M., Mogilski, S., Filipek, B., and M arona, H. (2013b). The hypotensive 
activity and alpha1-adrenoceptor antagonistic properties of some aroxyalkyl 
derivatives of 2-methoxyphenylpiperazine. Eur. J. Pharmacol. 698, 335-344. 
doi: 10.1016/j.ejphar.2012.10.025 
Kurtzwald-Josefson, E., Hochhauser, E., Bogachenko, K., H arun-K hun, S., 
Katz, G., Aravot, D., et al. (2014). Alpha blockade potentiates CPVT 
therapy in calsequestrin-m utant mice. H eart Rhythm  11, 1471-1479. doi: 
10.1016/j.hrthm.2014.04.030 
Lee, J. H., and Rosen, M. R. (1993). M odulation of delayed afterdepolarisations by 
alpha 1 adrenergic receptor subtypes. Cardiovasc. Res. 27, 839-844.
Litchfield, J. T., and Wilcoxon, F. (1949). A simplified m ethod of evaluating 
dose-effect experiments. J. Pharmacol. Exp. Ther. 96, 99-113.
O ’Connell, T. D., Ishizaka, S., Nakamura, A., Swigart, P. M., Rodrigo, M. C., 
Simpson, G. L., et al. (2003). The alpha(1A/C)- and alpha(1B)-adrenergic 
receptors are required for physiological cardiac hypertrophy in the double­
knockout mouse. J. Clin. Invest. 111, 1783-1791. doi: 10.1172/JCI16100 
Pares-Hipólito, J., Gómez-Żamudio, J. H., Gallardo-Ortiz, I. A., López-Guerrero, 
J. J., Santamaria-Ortiz, J., Ibarra, M., et al. (2006). Selective agonists reveal 
alpha(1A)- and alpha(1B)-adrenoceptor subtypes in caudal artery of the
Frontiers in Pharmacology | www.frontiersin.org 13 August 2016 | Volume 7 | Article 229
Pytka et al. a 1A-adrenolytics Attenuate Adrenaline-Induced Arrhythmia
young rat. Auton. Autacoid Pharmacol. 26, 371-378. doi: 10.1111/j. 1474- 
8673.2006.00380.x
Pönicke, K., H einroth-H offm ann, I., and Brodde, O.-E. (2002). Differential effects 
of bucindolol and carvedilol on noradenaline-induced hypertrophic response 
in ventricular cardiomyocytes of adult rats. J. Pharmacol. Exp. Ther. 301,71-76. 
doi: 10.1124/jpet.301.1.71 
Proven, A., Roderick, H. L., Conway, S. J., Berridge, M. J., H orton, J. K., Capper, S. 
J., et al. (2006). Inositol 1,4,5-trisphosphate supports the arrhythm ogenic action 
ofendothelin-1 on ventricular cardiac myocytes. J. CellSci. 119, 3363-3375. doi: 
10.1242/jcs.03073
Pytka, K., Partyka, A., Jastrzębska-Więsek, M., Siwek, A., Głuch-Lutwin, M., 
Mordyl, B., et al. (2015). A ntidepressant- and anxiolytic-like effects of new  dual 
5-HT1A and 5-HT7 antagonists in animal models. PLoS ONE  10:e0142499. doi: 
10.1371/journal.pone.0142499 
Rapacz, A., Pytka, K., Sapa, J., Kubacka, M., Filipek, B., Szkaradek, N., et al.
(2014). A ntiarrhythm ic, hypotensive and a1-adrenolytic properties of new 
2-methoxyphenylpiperazine derivatives of xanthone. Eur. J. Pharmacol. 735, 
10-16. doi: 10.1016/j.ejphar.2014.04.010
Rapacz, A., Sapa, J., Nowiiiski, L., Mogilski, S., Pytka, K., Filipek, B., et al. 
(2015a). Biofunctional studies of new 2-methoxyphenylpiperazine xanthone 
derivatives with a1ĆĄ-adrenolytic properties. Pharmacol. Rep. 67, 267-274. 
doi: 10.1016/j.pharep.2014.10.008 
Rapacz, A., Sapa, J., Pytka, K., Dudek, M., Filipek, B., Szkaradek, N., et al. 
(2015b). A ntiarrhythm ic activity of new 2-methoxyphenylpiperazine xanthone 
derivatives after ischemia/reperfusion in rats. Pharmacol. Rep. 67, 1163-1167. 
doi: 10.1016/j.pharep.2015.03.011 
Sapa, J., Filipek, B., and Nowrnski, L. (2011). A ntiarrhythm ic and hypotensive 
activities of 1-[2-hydroxy-3-(4-phenyl-1-piperazinyl)propyl]-pyrrolidin-2-one 
(MG-1(R,S)) and its enantiomers. Pharmacol. Rep. 63, 455-463. doi: 
10.1016/S1734-1140( 11)70512-6 
Shannon, R., and Chaudhry, M. (2006). Effect of alpha1-adrenergic receptors in 
cardiac pathophysiology. Am . Heart J. 152, 842-850. 10.1016/j.ahj.2006.05.017 
Sovari, A. A. (2016). Cellular and molecular mechanisms of arrhythm ia by 
oxidative stress. Cardiol. Res. Pract. 2016, 1-7. doi: 10.1155/2016/9656078 
Suita, K., Fujita, T., Hasegawa, N., Cai, W., Jin, H., Hidaka, Y., et al.
(2015). Norepinephrine-induced adrenergic activation strikingly increased the 
atrial fibrillation duration through ß1- and a1-adrenergic receptor-mediated 
signaling in mice. PLoS ONE  10:e0133664. doi: 10.1371/journal.pone.0133664
Szekeres, L., and Papp, J. G. (1968). Antiarrhythm ic compounds. Prog. drug 
Res. Fortschritte der Arzneimittelforschung. Progres des Rech. Pharm. 12, 
292-369.
Szekeres, L., and Papp, J. G. (1975). “Experimental cardiac arrhythm ias" in 
Experimental Production o f Diseases, Part 3, Heart and Circulation, Handbook 
ofExperimental Pharmacology, Vol. XVI/3, eds J. Schmier and O. Eichler (New 
York, NY; Berlin; Heidelberg: Springer-Verlag), 131-182.
Waszkielewicz, A. M., Pytka, K., Rapacz, A., W ełna, E., Jarzyna, M., Satała, G., 
et al. (2015). Synthesis and evaluation of antidepressant-like activity of some 4- 
substituted 1-(2-methoxyphenyl)piperazine derivatives. Chem. Biol. Drug Des. 
85, 326-335. doi: 10.1111/cbdd. 12394 
Williamson, A. P., Seifen, E., Lindemann, J. P., and Kennedy, R. H. (1994). Alpha 
1a-adrenergic receptor mediated positive chronotropic effect in right atria 
isolated from  rats. Can. J. Physiol. Pharmacol. 72, 1574-1579.
Xie, L.-H., Chen, F., Karagueuzian, H. S., and Weiss, J. N. (2009). Oxidative-stress- 
induced afterdepolarizations and calmodulin kinase II signaling. Circ. Res. 104, 
79-86. doi: 10.1161/CIRCRESAHA.108.183475 
Yue, T. L., Cheng, H. Y., Lysko, P. G., McKenna, P. J., Feuerstein, R., Gu, J. L., 
et al. (1992). Carvedilol, a new vasodilator and beta adrenoceptor antagonist, 
is an antioxidant and free radical scavenger. J. Pharmacol. Exp. Ther. 263, 
92-98.
Żima, A. V., and Blatter, L. A. (2004). Inositol-1,4,5-trisphosphate- 
dependent C a(2+) signalling in cat atrial excitation-contraction coupling 
and arrhythmias. J. Physiol. 555, 607-615. doi: 10.1113/jphysiol.2003. 
058529
Conflict o f Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be construed as a potential conflict of interest.
Copyright © 2016Pytka, Lustyk, Zm udzka, Kotamka, Siwek, Zygmunt, Dziedziczak, 
Sniecikowska, Olczyk, Gałuszka, Smieja, Waszkielewicz, Marona, Filipek, Sapa and 
Mogilski. This is an open-access article distributed under the terms o f the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forum s is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is perm itted which does not 
comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org 14 August 2016 | Volume 7 | Article 229
